Menu
GWAS Study

Genetic Variants Associated with Acamprosate Treatment Response in Alcohol Use Disorder Patients: A Multiple Omics Study.

Ho MF, Zhang C, Wei L et al.

35016259 PubMed ID
GWAS Study Type
442 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HM
Ho MF
ZC
Zhang C
WL
Wei L
ZL
Zhang L
MI
Moon I
GJ
Geske JR
SM
Skime MK
CD
Choi DS
BJ
Biernacka JM
OT
Oesterle TS
FM
Frye MA
SM
Seppala MD
KV
Karpyak VM
LH
Li H
WR
Weinshilboum RM
Chapter II

Abstract

Summary of the research findings

Background and purpose: Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes.

442 individuals

Chapter III

Study Statistics

Key metrics and study information

442
Total Participants
GWAS
Study Type
No
Replicated
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.